Lucas Blanchard (@LucasBlch) header
Lucas Blanchard (@LucasBlch) profile picture

Postdoc in Jeffrey Ravetch lab @RockefellerUniv

New York
Joined March 2020
Photo by Lucas Blanchard (@LucasBlch)Photo by Lucas Blanchard (@LucasBlch)Photo by Lucas Blanchard (@LucasBlch)Photo by Lucas Blanchard (@LucasBlch)Photo by Lucas Blanchard (@LucasBlch)Photo by Lucas Blanchard (@LucasBlch)Photo by Lucas Blanchard (@LucasBlch)Photo by Lucas Blanchard (@LucasBlch)Photo by Lucas Blanchard (@LucasBlch)Photo by Lucas Blanchard (@LucasBlch)
Lucas Blanchard retweeted
Excited to share our study, published today in @CCR_AACR Can we harness CD40 agonism to treat bladder cancer? And how spatial immune organization within tumors correlate with response? We report findings from a phase I trial of our Fc-engineered CD40 agonist. 🧵🪡 link 👇
1
9
34
2,428
Lucas Blanchard retweeted
Now online: Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: A Phase I Trial doi.org/10.1158/1078-0432.CC…
2
2
97
Targeting Myeloid Cells for Cancer Immunotherapy: doi.org/10.1158/2326-6066.CI… @juanosoriomd @LucasBlch
1
32
3
99
5,022
Lucas Blanchard retweeted
Our review on myeloid-targeting therapies in cancer immunotherapy is out in @CIR_AACR ! 🔬 We highlight recent advances, key challenges, and opportunities for translating these tx to the clinic. Huge thx to @LucasBlch for leading this work and Andrew Mijacika!
1
1
6
272
Thrilled to share our new publication on the first-in-human phase 1 trial of intratumoral Fc-engineered CD40 agonistic antibody 2141-V11 in metastatic cancer. Over 10 years of preclinical work led to this moment, made possible by an amazing team! 🧵 🪡 cell.com/cancer-cell/fulltex…
9
21
5
95
8,326
Lucas Blanchard retweeted
Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NSCLC, TNBC, GI + bladder cancers, melanoma and many more: written with close friends and KOLs published today in @NatureCancer @lab_kok doi.org/10.1038/s43018-025-0…
5
58
268
16,627
🚨 REVIEW🚨 Vignali & colleagues outline the various contributions of #Tregs to tumour progression & highlight ways in which they represent an attractive #nextgen immunotherapeutic target. 📖 👇 bit.ly/4mVxI8n
1
14
2
52
3,356
Thank you ACIR for highlighting our recent study ! 🎉
Blanchard and Vina et al. investigated mechanisms by which anti-CTLA-4 mAbs modulate tumor-associated high endothelial venules (TA-HEVs), which are important for supporting lymphocyte entry into tumors. bit.ly/4dNZyzu  @LucasBlch
2
78
We have previously shown that TA-HEVs are critical blood vessels that mediate lymphocyte entry into tumors during cancer immunotherapy, which suggested that strategies increasing TA-HEVs could improve treatment efficacy in non-responsive 'cold' tumors. sciencedirect.com/science/ar…
26
🚨 PLEASE SHARE! Early-career bladder cancer researchers: Apply now for BCAN's 2025 Young Investigator Awards! $75K in funding, mentorship, and networking opportunities await. Advance your research and career. 🧬 Deadline: Feb 21, 2025. Click for info: bcan.org/bcan-research/grant… [AI image]
11
11
2,933
Lucas Blanchard retweeted
Long awaited practice-changing results from ph 3 CM8HW now out in @TheLancet. Nivo/ipi sign better than nivo mono in dMMR mCRC @sara_lonardi1 @bmsnews #GI25 thelancet.com/journals/lance…
4
38
3
121
13,907
Lucas Blanchard retweeted
Just published📢 Our new forum article on Fc-optimized checkpoint antibodies for cancer therapy. New to immunotherapy and antibody engineering? This one’s for you! Co-authored with Alan Korman. @TrendsMolecMed #CancerImmunotherapy #FcEngineering sciencedirect.com/science/ar…
6
24
2,305
Lucas Blanchard retweeted
Check out our latest paper “Differentiation fate of a stem-like CD4 T cell control immunity to cancer”, led by @Maria_Carden1 now live @Nature tinyurl.com/33d24k89 . This work examines how CD4 T cell differentiation dictates the outcome of the cancer response. Thread below
9
56
5
202
33,870
Lucas Blanchard retweeted
How do T cells reach melanoma brain tumors? Using in vivo microscopy, we discovered a new route for T cells to enter the brain via distinct peri-tumoral venous vessels. Our newest paper is now online @ImmunityCP. authors.elsevier.com/sd/arti… A 🧵👇
8
31
4
129
25,286
Grateful and honored that our project on the therapeutic targeting of regulatory T cells (Tregs) was selected by @BladderCancerUS 🙏🏻 Let’s deplete these Tregs ! @RockefellerUniv
Welcome to the cohort, Lucas Blanchard, PhD (@LucasBlch)! Dr. Blanchard has received a BCAN 2024 Young Investigator Award. You can learn more about his research proposal and the award here: bcan.org/bcan-announces-four…
1
18
1,352
Lucas Blanchard retweeted
To improve agonist CD40 Abs for clinical use, Osorio, Knorr, Weitzenfeld, et al. evaluated 2141-V11, an Fc-engineered anti-CD40 (with optimized FcγRIIB binding) in a phase 1 study (12 patients). bit.ly/4cJhCcg  @RockefellerUniv
1
8
519